The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

TIL-based Therapies Market by Target Indications (Melanoma, Head and Neck Cancer, Breast Cancer, Hepatocellular Cancer, Sarcoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, and Cervical Cancer), Key Players and Key Geographies (North America, Europe and Asia Pacific): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    April 2021

  • Pages
    260

  • View Count
    172

Example Insights

TIL-based-Therapies-Market-Context TIL-based-Therapies-Market-Range-of-oncological-indications TIL-based-Therapies-Market-Majority-of-therapy-candidates
TIL-based-Therapies-Market-Key-Opinion-Leaders TIL-based-Therapies-Market-Partnerships-and-Collaborations TIL-based-Therapies-Market-Funding-and-Investments
TIL-based-Therapies-Market-promotional-strategies TIL-based-Therapies-Market-List-of-Cell-Therapy-Manufacturers TIL-based-Therapies-Market-Future-Forecast

Overview

The inadequacy of legacy pharmacological interventions, such as chemotherapy, radiation therapy, and surgery, in addressing the complex treatment-related needs of cancer patients, have paved way for more effective and versatile alternatives. Amidst the current initiatives to develop targeted anti-cancer therapies, modified tumor-infiltrating lymphocytes (TIL)-based interventions have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects. Till date, several clinical trials have demonstrated efficacy and therapeutic superiority (over conventional treatment options) of TIL-based therapies. Their tumor-cell killing efficiencies are attributed to the fact that they are pre-sensitized to cancer specific antigens. The contemporary TIL-based therapies market is characterized by a healthy and growing pipeline of close to 60 product candidates; in fact, more than 28 of such therapies, including CCRT+TIL (Sun Yat-sen University), Lifileucel (Iovance Biotherapeutics), LTX-315 and TILs (Lytix Biopharma / Herlev Hospital), and IOV-2001 (Iovance Biotherapeutics), are in the advanced stages of development. The first TIL-based therapy, LN-145 being developed by Iovance Biotherapeutics, is expected to get approval in 2022. Given the therapeutic benefits that they have displayed thus far, it is likely that the lucrative opportunities await the companies having the required capabilities to develop and manufacture TIL-based therapies, in the foreseen future.

Over time, the clinical success of several TIL-based immunotherapy candidates, have inspired numerous research groups across the world, to focus their efforts on this relatively novel class of anti-cancer therapies. Post 2014, the interest in T-cell therapies, including those involving TILs, has grown exponentially. Moreover, a substantial body of evidence favoring the therapeutic benefits of TIL-based therapies, has prompted the establishment of numerous strategic partnerships (focused on therapy development and clinical research) and caused several public and private investors to put in significant capital into innovator companies involved in this domain. Promising clinical results, and ongoing technical developments, coupled to the growing interest of biopharmaceutical developers, are anticipated to enable the rapid progression of pipeline candidates into higher phases of development and eventually, into the market. We are led to believe that the global TIL-based therapies market is poised to witness significant growth in the foreseen future.

Scope of the Report

The “TIL-based Therapies Market by Target Indications (Melanoma, Head and Neck Cancer, Breast Cancer, Hepatocellular Cancer, Sarcoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, and Cervical Cancer), Key Players and Key Geographies (North America, Europe and Asia Pacific) – Global Forecast 2021-2030” report features an extensive study of the current market landscape and future potential of TIL-based therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of TIL-based therapies with respect to type of developer (industry / non-industry), phase of development (preclinical, phase I, phase I/II and phase II), therapeutic area (hematological cancer, solid tumor and others), popular target indications (melanoma, ovarian cancer, pancreatic cancer, head and neck cancer, sarcoma, colon cancer, acute myeloid leukemia, stomach cancer, chronic lymphocytic leukemia, cervical cancer, breast cancer and others), source of T-cells (autologous and allogeneic), dose frequency (single dose, multiple dose and split dose), target patient segment (children, adults and elderly patients) and type of therapy (monotherapy and combination therapy). Further, the chapter provides detail on the most active players (in terms of number of pipeline candidates) engaged in this domain. 
  • An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix assessing the relative experience of KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) in this field, and a schematic world map representation, indicating the geographical location of eminent scientists / researchers engaged in the development of TIL-based therapies.
  • Detailed profiles of therapies being evaluated in clinical stages (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, current development status, key clinical trial results, dosage regimen and manufacturing information.
  • An overview of key therapeutic areas that are being targeted by TIL-based therapies. It also includes an assessment of the opportunity (in terms of revenue generation potential from therapy sales) across oncological disease indications.
  • An analysis of the partnerships that have been established in the recent past, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
  • An analysis of investments that have been made into companies which have proprietary TIL-based products / technologies. The various type of funding instances reported in this domain include seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants, and debt financing.
  • A case study on manufacturing of cell therapy products, highlighting the key challenges associated with the production of such therapies. In addition, it features a detailed list of contract service providers and in-house manufacturers engaged in this market.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may adopt, in order to decide the price of a TIL-based therapy.
  • A review of the key promotional strategies that have been adopted by developers of marketed T-cell therapies, namely KYMRIAH® and YESCARTA®.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for TIL-based therapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2021-2030. The report also includes likely sales forecasts of TIL-based therapies that are in the mid- to late stages of development. Additionally, it features market size projections for the overall TIL-based therapies market, wherein both the current and upcoming opportunity is segmented across [A] target indications (melanoma, head and neck cancer, breast cancer, hepatocellular cancer, sarcoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, and cervical cancer), [B] key players and [D] key geographies (North America, Europe, Asia Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Question Answered

  • What are the prevalent R&D trends related to TIL-based therapies?
  • Which are the key therapeutic areas targeted by TIL-based therapies?
  • Who are the leading industry and non-industry players engaged in the development of TIL-based therapies?
  • What challenges are commonly faced by stakeholders engaged in this domain?
  • Who are the key investors in this domain? 
  • Who are the key opinion leaders / experts engaged in this upcoming field of therapeutics?
  • Which types of partnership models are commonly adopted by industry stakeholders? 
  • Which are the key regions where contract manufacturing support is available for TIL-based therapies?
  • What are the different types of promotional strategies that are likely to be adopted for approved / yet to be commercialized TIL-based therapies?
  • Which factors are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the TIL-based therapies market in the short to mid-term and long term.

Chapter 3 provides a general overview of TIL-based therapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of TIL-based therapies, factors supporting the growing popularity of such therapy candidates and the challenges associated with these products. 

Chapter 4 includes detailed assessment on more than 65 TIL-based therapies that are currently approved or are in different stages of development. It features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry / non-industry), phase of development (preclinical, phase I, phase I/II and phase II), therapeutic area (hematological cancer, solid tumor and others), popular target indications (melanoma, ovarian cancer, pancreatic cancer, head and neck cancer, sarcoma, colon cancer, acute myeloid leukemia, stomach cancer, chronic lymphocytic leukemia, cervical cancer, breast cancer and others), source of T-cells (autologous and allogeneic), dose frequency (single dose, multiple dose and split dose), target patient segment (children, adults and elderly patients), and type of therapy (monotherapy and combination therapy). Further, the chapter provides a list of the most active players (in terms of number of pipeline candidates)

Chapter 5 features an analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix representation highlighting the KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, indicating the geographical location of eminent scientists / researchers involved in the development of TIL-based therapies.

Chapter 6 provides detailed profiles of TIL-based therapies in developmental stages (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, current development status, and key clinical trial results.

Chapter 7 identifies the most commonly targeted therapeutic indications, including hematological cancers and solid tumors and features brief discussions on the TIL-based therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.

Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed based on various parameters, such as type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.

Chapter 9 provides details on the various investments and grants that have been awarded to players focused on the development of TIL-based therapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2020, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 10 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a detailed list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 11 highlights our views on the various factors that must be taken into consideration while deciding the prices of TIL-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their TIL-based therapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for CAR-T cell therapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of for CAR-T cell therapies.

Chapter 12 includes brief company profiles of the leading players in the TIL-based therapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to technology portfolio (if available), recent developments related to TIL-based therapy and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 13 features an elaborate discussion on the future commercial opportunity offered by TIL-based therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II and phase II of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation based on  [A] target indications (melanoma, head and neck cancer, breast cancer, hepatocellular cancer, sarcoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, and cervical cancer), [B] key players and [C] key geographies (North America, Europe and Asia Pacific).

Chapter 14 highlights the key promotional strategies that are being implemented by the developers of the marketed products, KYMRIAH® and YESCARTA®. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 15 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 16 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Peter Ho (Director, Process Development, Iovance Biotherapeutics)

Chapter 17 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 18 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapy
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy

3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies

3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution of T-Cell Immunotherapies
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing Process of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods

3.7. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapies
3.7.1. Historical Evolution
3.7.2. Development of TIL-based Therapies
3.7.3. Key Challenges and Roadblocks Associated with the Development of TIL 
3.8. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. TIL-based Therapies: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Popular Target Indications
4.2.5. Analysis by Source of T-Cells
4.2.6. Analysis by Dose Frequency
4.2.7. Analysis by Target Patient Segment
4.2.8. Analysis by Type of Therapy
4.2.9. Key Industry Players: Analysis by Number of TIL-based Therapies 
4.2.10. Key Non-Industry Players: Analysis by Number of TIL-based Therapies 

5. KEY OPINION LEADERS ANALYSIS
5.1. Chapter Overview
5.2. TIL-based Therapies: Key Opinion Leaders
5.2.1. TIL-based Therapies: Most Prominent Key Opinion Leaders

6. TIL-BASED THERAPY PROFILES
6.1. Chapter Overview
6.2. Autologous TIL Therapies (Iovance Biotherapeutics)
6.2.1. Therapy Overview
6.2.2. Current Development Status
6.2.2.1. LN-144
6.2.2.2. LN-145
6.2.3. Key Clinical Trial Results
6.2.3.1. LN-144
6.2.3.2. LN-145
6.2.4. Dosage Regimen and Manufacturing
6.2.5. Patent Portfolio

6.3. TIL (Nantes University Hospital)
6.3.1. Therapy Overview
6.3.2. Current Development Status
6.3.3. Key Clinical Trial Results
6.3.4. Dosage Regimen and Manufacturing

6.4. TIL (Netherlands Cancer Institute)
6.4.1. Therapy Overview
6.4.2. Current Development Status
6.4.3. Key Clinical Trial Results
6.4.4. Dosage Regimen and Manufacturing

7. KEY THERAPEUTIC AREAS FOR TIL-BASED THERAPIES
7.1. Chapter Overview
7.2. Hematological Malignancies
7.2.1. Leukemia and Lymphoma
7.2.1.1. Leukemia: Introduction and Epidemiology
7.2.1.2. Lymphoma: Introduction and Epidemiology
7.2.1.3. Current Treatment Landscape
7.2.1.3.1. Targeted Therapies
7.2.1.4. TIL-based Therapies and Affiliated Research Landscape
7.2.1.4.1. TIL-based Therapies and Leukemia

7.3. Solid Tumors
7.3.1. Metastatic Melanoma
7.3.1.1. Introduction and Epidemiology
7.3.1.2. Current Treatment Landscape
7.3.1.3. TIL-based Therapies and Affiliated Research Landscape

7.3.2. Pancreatic Cancer
7.3.2.1. Introduction and Epidemiology
7.3.2.2. Current Treatment Landscape
7.3.2.3. TIL-based Therapies and Affiliated Research Landscape

7.3.3. Liver Cancer
7.3.3.1. Current Treatment Landscape
7.3.3.2. TIL-based Therapies and Affiliated Research Landscape

7.3.4. Breast Cancer
7.3.4.1. Introduction and Epidemiology
7.3.4.2. Current Treatment Landscape
7.3.4.3. TIL-based Therapies and Affiliated Research Landscape

7.3.5. Ovarian Cancer
7.3.5.1. Introduction and Epidemiology
7.3.5.2. Current Treatment Landscape
7.3.5.3. TIL-based Therapies and Affiliated Research Landscape

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8..2. Types of Partnership Models
8.3. TIL-based Therapies: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Partner
8.3.4. Most Active Industry Players: Analysis by Number of Partnerships
8.3.5. Most Active Non-Industry Players: Analysis by Number of Partnerships
8.3.6. Most Active Contract Manufacturers: Analysis by Number of Manufacturing 
8.3.7. Analysis by Geography
8.3.7.1. Region-wise Distribution
8.3.7.2. Country-wise Distribution

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. TIL-based Therapies: Funding and Investment Analysis
9.3.1. Analysis by Year of Investment
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Most Active Players: Analysis by Number of Funding Instances
9.3.5. Analysis by Type of Investor
9.3.6. Most Active Investors: Analysis by Number of Funding Instances
9.3.7. Regional Analysis by Amount Invested

10. CASE STUDY: CELL THERAPY MANUFACTURING
10.1. Chapter Overview
10.2. Overview of Cell Therapy Manufacturing
10.3. Cell Therapy Manufacturing Models
10.3.1. Centralized Manufacturing Model
10.3.2. Decentralized Manufacturing Model
10.4. Scalability of Cell Therapy Manufacturing Processes
10.4.1. Scale-up
10.4.2. Scale-out
10.5. Types of Cell Therapy Manufacturers
10.6. Key Challenges associated with Manufacturing of Cell Therapies
10.7. Factors Affecting the Process of Cell Therapy Manufacturing
10.7.1. Characterization
10.7.2. Cost of Goods
10.8. Automation of Cell Therapy Manufacturing Processes
10.9. Cell Therapy Manufacturing Supply Chain
10.10. Companies with In-House Capabilities
10.11. Contract Manufacturers
10.12. Regulatory Landscape

11. COST PRICE ANALYSIS
11.1. Chapter Overview
11.2. Factors Contributing to the High Price of Cell / Gene Therapies
11.3. Pricing Models for T-Cell Therapies
11.3.1. Based on Associated Costs
11.3.2. Based on Availability of Competing Products
11.3.3. Based on Target Patient Segment
11.3.4. Based on the Opinions of Industry Experts
11.4. Reimbursement-related Considerations for T-Cell Therapies
11.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Cell Therapies

12. COMPANY PROFILES
12.1. Chapter Overview
12.2. Cellular Biomedicine Group
12.3. Iovance Biotherapeutics
12.4. Lytix Biopharma
12.5. Phio Pharmaceuticals

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Scope and Limitations
13.3. Key Assumptions and Forecast Methodology

13.4. Overall TIL-based Therapies Market
13.4.1. TIL-based Therapies Market: Distribution by Target Indication
13.4.2. TIL-based Therapies Market:  Distribution by Key Players
13.4.3. TIL-based Therapies Market: Distribution by Geography

13.4.3.1. TILs (Netherlands Cancer Institute)
13.4.3.1.1. Target Patient Population
13.4.3.1.2. Sales Forecast (USD Million)
13.4.3.1.3. Net Present Value (USD Million)
13.4.3.1.4. Value Creation Analysis

13.4.3.2. Lifileucel (LN-144) (Iovance Biotherapeutics)
13.4.3.2.1. Target Patient Population
13.4.3.2.2. Sales Forecast (USD Million)
13.4.3.2.3. Net Present Value (USD Million)
13.4.3.2.4. Value Creation Analysis

13.4.3.3. LN-145 (Iovance Biotherapeutics)
13.4.3.3.1. Target Patient Population
13.4.3.3.2. Sales Forecast (USD Million)
13.4.3.3.3. Net Present Value (USD Million)
13.4.3.3.4. Value Creation Analysis

13.4.3.4. IOV-2001 (Iovance Biotherapeutics)
13.4.3.4.1. Target Patient Population
13.4.3.4.2. Sales Forecast (USD Million)
13.4.3.4.3. Net Present Value (USD Million)
13.4.3.4.4. Value Creation Analysis

13.4.3.5. LTX-315 and TILs (Lytix Biopharma)
13.4.3.5.1. Target Patient Population
13.4.3.5.2. Sales Forecast (USD Million)
13.4.3.5.3. Net Present Value (USD Million)
13.4.3.5.4. Value Creation Analysis

13.4.3.6. Allogeneic donor lymphocyte infusions (DLI) (Amgen / University of Munich)
13.4.3.6.1. Target Patient Population
13.4.3.6.2. Sales Forecast (USD Million)
13.4.3.6.3. Net Present Value (USD Million)
13.4.3.6.4. Value Creation Analysis

13.4.3.7. TILs (CAR-T (Shanghai) Cell Biotechnology) (CAR-T (Shanghai) Cell 
13.4.3.7.1. Target Patient Population
13.4.3.7.2. Sales Forecast (USD Million)
13.4.3.7.3. Net Present Value (USD Million)
13.4.3.7.4. Value Creation Analysis

14. PROMOTIONAL ANALYSIS
14.1. Chapter Overview
14.2. Channels Used for Promotional Campaigns
14.3. Summary of Product Website Analysis
14.4. Summary of Patient Support Services and Informative Downloads

14.5. KYMRIAH®: Promotional Analysis
14.5.1. Drug Overview
14.5.2. Product Website Analysis
14.5.2.1. Messages for Healthcare Professionals
14.5.2.2. Messages for Patients
14.5.3. Patient Support Services and Informative Downloads
14.5.4. Other Promotional Activities
14.5.4.1. Presence in Conferences

14.6. YESCARTA®: Promotional Analysis
14.6.1. Drug Overview
14.6.2. Product Website Analysis
14.6.2.1. Messages for Healthcare Professionals
14.6.2.3. Messages for Patients
14.6.3. Patient Support Services and Informative Downloads
14.6.4. Other Promotional Activities
14.6.4.1. Presence in Conferences

15. CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Iovance Biotherapeutics
16.2.1. Interview Transcript: Peter Ho, Director, Process Development

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Pillars of Cancer Therapy
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Comparison of Active and Passive Immunotherapies
Figure 3.3 Comparison of Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 TIL-based Therapies: Development Process
Figure 3.7 Challenges Associated with TIL-based Therapies
Figure 3.8 TIL-based Therapies: Benefits and Key Challenges
Figure 4.1 TIL-based Therapies: Distribution by Type of Developer
Figure 4.2 TIL-based Therapies: Distribution by Phase of Development
Figure 4.3 TIL-based Therapies: Distribution by Therapeutic Area
Figure 4.4 TIL-based Therapies: Distribution by Popular Target Indications
Figure 4.5 TIL-based Therapies: Distribution by Source of T-Cells
Figure 4.6 TIL-based Therapies: Distribution by Dose Frequency
Figure 4.7 TIL-based Therapies: Distribution by Target Patient Segment
Figure 4.8 TIL-based Therapies: Distribution by Type of Therapy
Figure 4.9 TIL-based Therapies: Most Active Industry Players by Number of Therapies in Clinical Development Pipeline
Figure 4.10 TIL-based Therapies: Most Active Industry Players by Number of Therapies in Preclinical Development Pipeline
Figure 4.11 TIL-based Therapies: Most Active Non-Industry Players by Number of Therapies in Clinical Development Pipeline
Figure 5.1 TIL-based Therapies: Geographical Distribution of Key Opinion Leaders
Figure 5.2 TIL-based Therapies: Prominent Key Opinion Leaders
Figure 6.1 Nantes University Hospital’s TIL Therapy: Production Procedure
Figure 7.1 Leukemia: Classification
Figure 7.2 Leukemia: Global Epidemiological Distribution
Figure 7.3 Lymphoma: Global Epidemiological Distribution
Figure 7.4 Metastatic Melanoma: Global Epidemiological Distribution
Figure 7.5 Pancreatic Cancer: Global Epidemiological Distribution
Figure 7.6 Liver Cancer: Global Epidemiological Distribution
Figure 7.7 Breast Cancer: Global Epidemiological Distribution
Figure 7.8 Ovarian Cancer: Global Epidemiological Distribution
Figure 7.9 Bladder Cancer: Global Epidemiological Distribution
Figure 8.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2011-2020
Figure 8.2 Partnerships and Collaborations: Distribution by Year and Type of Partner, Pre-2011-2020
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Pre-2015 and 2015-2020
Figure 8.5 Partnerships and Collaborations: Most Active Industry Players
Figure 8.6 Partnerships and Collaborations: Most Active Non-Industry Players
Figure 8.7 Partnerships and Collaborations: Most Active Contract Manufacturers
Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Manufacturing Agreements
Figure 8.9 Partnerships and Collaborations: Regional Distribution
Figure 8.10 Partnerships and Collaborations: Intercontinental and IntracontinentalDistribution
Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2013 - 2020 (till October)
Figure 9.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested, Pre-2013 - 2020 (USD Million)
Figure 9.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 9.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 9.5 Most Active Players: Distribution by Number of Funding Instances
Figure 9.6 Funding and Investment: Distribution by Type of Investor
Figure 9.7 Most Active Players: Distribution by Number of Funding Instances
Figure 9.8 Funding and Investment Analysis: Distribution by Geography
Figure 9.9 Funding and Investment Analysis: Distribution of Amount Invested across Different Countries (USD Million)
Figure 10.1 Steps in Cell Therapy Manufacturing Process
Figure 10.2 Centralized Manufacturing: Process Model
Figure 10.3 Decentralized Manufacturing: Process Model
Figure 10.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 10.5 Cell Therapy Manufacturing: Challenges and Drivers
Figure 10.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 10.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 10.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 11.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 13.1 Overall TIL-based Therapies Market, 2021-2030 (USD Billion)
Figure 13.2 TIL-Based Therapies Market: Distribution by Target Indication(s), 2025 and 2030(USD Billion)
Figure 13.3 TIL-Based Therapies Market: Distribution by Key Players, 2025 and 2030(USD Billion)
Figure 13.4 TIL-Based Therapies Market: Distribution by Geography, 2025 and 2030(USD Billion)
Figure 13.5 TILs (Netherland Cancer Institute): Current Status of Development
Figure 13.6 TILs (Netherland Cancer Institute) Sales Forecast, till 2030 (USD Million)
Figure 13.7 Lifileucel (LN-144) (Iovance Biotherapeutics): Current Status of Development
Figure 13.8 Lifileucel (LN-144) Sales Forecast, till 2030 (USD Million)
Figure 13.9 LN-145 (Iovance Biotherapeutics): Current Status of Development
Figure 13.10 LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 13.11 IOV-2001 (Iovance Biotherapeutics): Current Status of Development
Figure 13.12 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 13.13 LTX-315 and TILs (Lytix Biopharma): Current Status of Development
Figure 13.14 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030 (USD Million)
Figure 13.15 Allogeneic donor lymphocyte infusions (DLI) (University of Munich, Amgen):Current Status of Development
Figure 13.16 Allogeneic donor lymphocyte infusions (DLI) (University of Munich, Amgen)Sales Forecast, till 2030 (USD Million)
Figure 13.17 TILs (CAR-T (Shanghai) Cell Biotechnology / Eastern Hepatobiliary SurgeryHospital): Current Status of Development
Figure 13.18 TILs (CAR-T (Shanghai) Cell Biotechnology / Eastern Hepatobiliary SurgeryHospital) Sales Forecast, till 2030 (USD Million)
Figure 14.1 Channels Used for Promotional Campaigns
Figure 14.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 14.3 Promotional / Marketing Strategy: Patient Support Services and InformativeDownloads
Figure 14.4 Product Website Analysis: KYMRIAH®, Messages for Healthcare Professionals
Figure 14.5 Product Website Analysis: KYMRIAH®, Messages for Patients
Figure 14.6 Product Website Analysis: KYMRIAH®, Patient Support Program
Figure 14.7 KYMRIAH®: Presence in Conferences
Figure 14.8 Product Website Analysis: YESCARTA®, Messages for HealthcareProfessionals
Figure 14.9 Product Website Analysis: YESCARTA®, Messages for Patients
Figure 14.10 Product Website Analysis: YESCARTA®, Kite Konnect
Figure 14.11 Product Website Analysis: YESCARTA®, Platform for Reporting AdverseEvents / Product Complaints and Requesting Medical Information
Figure 14.12 YESCARTA®: Presence in Conferences
Figure 15.1 Concluding Remarks: Overall Market Landscape
Figure 15.2 Concluding Remarks: Partnerships and Collaborations and Funding and Investment Analysis
Figure 15.3 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody based Cancer Therapeutics
Table 4.1 TIL-based Therapies: Clinical Pipeline
Table 4.2 TIL-based Therapies: Preclinical Pipeline
Table 5.1 TIL-based Therapies: Principal Investigators
Table 6.1 LN-144: Clinical Studies
Table 6.2 LN-144: Clinical Trial Endpoints
Table 6.3 LN-145: Current Status of Development
Table 6.4 LN-145: Clinical Trial Endpoints
Table 6.5 LN-144: Patent Portfolio
Table 6.6 Nantes University Hospital’s TIL Therapy: Clinical Trial Endpoints
Table 6.7 Netherlands Cancer Institute’s TIL Therapy: Clinical Trial Endpoints
Table 6.8 Phase I/II or Phase II TIL-based Cell Therapies from the Industry Players
Table 7.1 Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 7.2 Leukemia: List of Marketed Targeted Therapeutics
Table 7.3 Lymphoma: List of Marketed Targeted Therapeutics
Table 7.4 Metastatic Melanoma: List of Marketed Targeted Therapeutics
Table 7.5 Pancreatic Cancer: List of Marketed Targeted Therapeutics
Table 7.6 Liver Cancer: List of Marketed Targeted Therapeutics
Table 7.7 TIL-based Therapies: Targets under Investigation for Liver Cancer
Table 7.8 Breast Cancer: List of Marketed Targeted Therapeutics
Table 7.9 TIL-based Therapies: Targets under Investigation for Breast Cancer
Table 7.10 Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 7.11 Bladder Cancer: List of Marketed Targeted Therapeutics
Table 8.1 TIL-based Therapies Market: List of Partnerships and Collaborations, 2011-2020 (till October)
Table 9.1 TIL-based Therapies: Funding and Investments, 2000-2020 (till October)
Table 9.2 TIL-based Therapies: Summary of Investments
Table 10.1 Assessment Strategies for Different Manufacturing Processes
Table 10.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 10.3 Cell Therapy Manufacturing: Companies with In-house Capabilities
Table 10.4 Cell Therapy Manufacturing: Contract Manufacturers
Table 11.1 Price of Marketed Cell / Gene Therapies
Table 11.2 Price of Marketed Targeted Drugs
Table 11.3 TIL-based Therapies: Expert Opinions on Pricing
Table 11.4 TIL-based Therapies: Reimbursement Landscape
Table 12.1 Cellular Biomedicine Group: Company Profile
Table 12.2 Iovance Biotherapeutics: Company Profile
Table 12.3 Lytix Biopharma: Company Profile
Table 12.4 Phio Pharmaceuticals: Company Profile
Table 13.1 TIL-based Therapies: List of Forecasted Molecules
Table 13.2 TILs (Netherland Cancer Institute): Net Present Value (USD Million)
Table 13.3 TILs (Netherland Cancer Institute): Value Creation Analysis (USD Million)
Table 13.4 Lifileucel (LN-144) (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 13.5 TILs (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 13.6 LN-145 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 13.7 LN-145 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 13.8 IOV-2001 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 13.9 IOV-2001 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 13.10 LTX-315 and TILs (Lytix Biopharma): Net Present Value (USD Million)
Table 13.11 LTX-315 and TILs (Lytix Biopharma): Value Creation Analysis (USD Million)
Table 13.12 Allogeneic Donor Lymphocyte Infusions (DLI) (Amgen / University of Munich):Net Present Value (USD Million)
Table 13.13 Allogeneic Donor Lymphocyte Infusions (DLI) (Amgen / University of Munich:Value Creation Analysis (USD Million)
Table 13.14 TILs (CAR-T (Shanghai) Cell Biotechnology / Eastern Hepatobiliary SurgeryHospital): Net Present Value (USD Million)
Table 13.15 TILs (CAR-T (Shanghai) Cell Biotechnology / Eastern Hepatobiliary SurgeryHospital): Value Creation Analysis (USD Million)
Table 14.1 Kymriah®: Drug Overview
Table 14.2 Yescarta®: Drug Overview
Table 17.1 TIL-based Therapies: Distribution by Type of Developer
Table 17.2 TIL-based Therapies: Distribution by Phase of Development
Table 17.3 TIL-based Therapies: Distribution by Target Therapeutic Area
Table 17.4 TIL-based Therapies: Distribution by Popular Target Indications
Table 17.5 TIL-based Therapies: Distribution by Source of T-Cells
Table 17.6 TIL-based Therapies: Distribution by Dose Frequency
Table17.7 TIL-based Therapies: Distribution by Target Patient Segment
Table 17.8 TIL-based Therapies: Distribution by Type of Therapy
Table 17.9 TIL-based Therapies: Active Industry Players by Number of Therapies in ClinicalDevelopment 
Table 17.10 TIL-based Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 17.11 TIL-based Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Table 17.12 TIL-based Therapies: Active Non-Industry Players by Number of Therapies inPreclinical Development
Table 17.13 TIL-based Therapies: Geographical Distribution of Key Opinion Leaders
Table 17.14 TIL-based Therapies: Prominent Key Opinion Leaders
Table 17.15 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2011-2020
Table 17.16 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.17 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Pre-2015 and 2015-2020
Table 17.18 Partnerships and Collaborations: Distribution by Type of Partner
Table 17.19 Partnerships and Collaborations: Distribution by Individual Products
Table 17.20 Partnerships and Collaborations: Most Active Industry Players
Table 17.21 Partnerships and Collaborations: Most Active Non-Industry Players
Table 17.22 Partnerships and Collaborations: Most Active Contract Manufacturers
Table 17.23 Partnerships and Collaborations: Intercontinental and IntracontinentalManufacturing Agreements
Table 17.24 Partnerships and Collaborations: Regional Distribution
Table 17.25 Partnerships and Collaborations: Intercontinental and IntracontinentalDistribution
Table 17.26 Funding and Investment Analysis: Cumulative Year-wise Trend of FundingInstances, Pre-2013 - 2020 (till October)
Table 17.27 Funding and Investment Analysis: Distribution by Cumulative Amount Invested,Pre-2013 - 2020 (USD Million)
Table 17.28 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 17.29 Funding and Investment Analysis: Distribution of Total Amount Invested byType of Funding (USD Million)
Table 17.30 Funding and Investments: Distribution by Amount Invested across DifferentTypes of Therapies, Pre-2012 - 2020 (Till October)
Table 17.31 Most Active Players: Distribution by Number of Instances
Table 17.32 Funding and Investments: Distribution by Types of Investor
Table 17.33 Most Active Players: Distribution by Number of Instances
Table 17.34 Funding and Investment Analysis: Distribution by Geography
Table 17.35 Funding and Investment Analysis: Distribution of Amount Invested acrossDifferent Countries (USD Million)
Table 17.36 Overall TIL-Based Cell Therapies Market, 2020-2030 Conservative, Base andOptimistic Scenarios, 2020-2030 (USD Million)
Table 17.37 TIL-Based Cell Therapies Market: Distribution by Target Indication(s), 2025 and2030 (USD Billion)
Table 17.38 TIL-Based Cell Therapies Market: Key Players, 2025 and 2030 (USD Billion)
Table 17.39 TIL-Based Cell Therapies Market: Distribution by Geography, 2025 and 2030(USD Billion)
Table 17.40 TILs (The Netherlands Cancer Institute) Sales Forecast, Conservative, Base andOptimistic Scenarios, till 2030 (USD Million)
Table 17.41 Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, Conservative,Base and Optimistic Scenarios, till 2030 (USD Million)
Table 17.42 LN-145 (Iovance Biotherapeutics) Sales Forecast, Conservative, Base andOptimistic Scenarios, till 2030 (USD Million)
Table 17.43 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, Conservative, Base andOptimistic Scenarios, till 2030 (USD Million)
Table 17.44 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, Conservative, Base andOptimistic Scenarios, till 2030 (USD Million)
Table 17.45 Allogeneic Donor Lymphocyte Infusions (DLI) (Amgen) Sales Forecast,Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 17.46 TILs (CAR-T (Shanghai) Cell Biotechnology) Sales Forecast, Conservative, Baseand Optimistic Scenarios, till 2030 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. Alexandria Real Estate Equities
  2. Amgen
  3. Astero Bio
  4. Autolus
  5. Beijing Cancer Hospital
  6. BioLife Solutions
  7. Blood Centers of America 
  8. Bristol-Myers Squibb
  9. CAR-T (Shanghai) Cell Biotechnology
  10. Casebia Therapeutics
  11. Cell and Gene Therapy Catapult
  12. Cellectis
  13. Cellular Biomedicine Group 
  14. Center for Cell and Gene Therapy
  15. Cognate BioServices
  16. CRISPR Therapeutics 
  17. Cryoport
  18. Dana-Farber Cancer Institute
  19. Eastern Hepatobiliary Surgery Hospital
  20. Fred Hutchinson Cancer Research Center
  21. H. Lee Moffitt Cancer Center and Research Institute
  22. Hadassah Medical Center
  23. Herlev Hospital
  24. Henan Cancer Hospital
  25. Herlev Hospital
  26. Immetacyte
  27. Incyte
  28. Intima Bioscience
  29. Intrexon
  30. Iovance Biotherapeutics
  31. Johns Hopkins University
  32. Karolinska Institutet
  33. Karolinska University Hospital
  34. Keio University
  35. Key Biologics
  36. KSQ Therapeutics
  37. Lausanne University Hospital
  38. Leukemia and Lymphoma Society
  39. Lonza
  40. Lyell Immunopharma
  41. Lytix Biopharma
  42. Marker Therapeutics
  43. Masonic Cancer Center
  44. Massachusetts General Hospital
  45. MaSTherCell
  46. MaxCyte
  47. MD Anderson Cancer Center
  48. MedImmune
  49. Merck
  50. Miltenyi Biotec
  51. Nantes University Hospital
  52. National Cancer Institute
  53. National Institutes of Health
  54. Oxford BioMedica
  55. PACT Pharma
  56. PharmaCell
  57. Phio Pharmaceuticals
  58. PolyBioCept
  59. Precision BioSciences
  60. Prometheus Laboratories
  61. Roswell Park Cancer Institute
  62. Sheba Medical Center
  63. Stratophase 
  64. Sun Yat-sen University
  65. Synthace 
  66. The Japanese Society for Regenerative Medicine
  67. The Netherlands Cancer Institute
  68. The Ohio State University 
  69. TILT Biotherapeutics
  70. Tongji Medical College of Huazhong University of Science and Technology
  71. TrakCel
  72. University of North Carolina (UNC) School of Medicine 
  73. University Health Network, Toronto
  74. University of California
  75. University of Manchester
  76. University of Minnesota
  77. University of Munich
  78. University of Pittsburgh
  79. V Foundation for Cancer Research
  80. Vineti
  81. WindMIL Therapeutics
  82. WuXi AppTec
  83. Yale University

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com